BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Fuji
McKinsey
Cantor Fitzgerald
Colorcon
Daiichi Sankyo
Boehringer Ingelheim
Cipla
US Department of Justice
Farmers Insurance

Generated: January 20, 2018

DrugPatentWatch Database Preview

Lamivudine; zidovudine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for lamivudine; zidovudine and what is the scope of lamivudine; zidovudine freedom to operate?

Lamivudine; zidovudine
is the generic ingredient in two branded drugs marketed by Viiv Hlthcare, Aurobindo Pharma Ltd, Hetero Labs Ltd Iii, Hetero Labs Ltd V, Lupin Ltd, Mylan Pharms Inc, Pharmacare, Strides Pharma, and Teva Pharms, and is included in ten NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Lamivudine; zidovudine has forty-one patent family members in twenty-eight countries.

There are twenty-eight drug master file entries for lamivudine; zidovudine. Twenty-three suppliers are listed for this compound. There are sixteen tentative approvals for this compound.
Summary for lamivudine; zidovudine
International Patents:41
US Patents:1
Tradenames:2
Applicants:9
NDAs:10
Drug Master File Entries: 28
Suppliers / Packagers: 23
Clinical Trials: 810
Drug Prices:see low prices
DailyMed Link:lamivudine; zidovudine at DailyMed
Tentative approvals for LAMIVUDINE; ZIDOVUDINE
Applicant Application No. Strength Dosage Form
➤ Subscribe➤ Subscribe150MG; 300MG; 200MGTABLET; ORAL
➤ Subscribe➤ Subscribe150MG; 300MG; 600MGTABLET; ORAL
➤ Subscribe➤ Subscribe150MG; 300MG; 300MGTABLET; ORAL

US Patents and Regulatory Information for lamivudine; zidovudine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 079081-001 May 25, 2011 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pharmacare LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 022018-001 Mar 17, 2017 BX RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Aurobindo Pharma Ltd LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 202418-001 May 15, 2012 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Pharms Inc LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 204005-001 Aug 28, 2014 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Aurobindo Pharma Ltd LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 077558-001 May 5, 2017 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lupin Ltd LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 090246-001 May 15, 2012 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Hetero Labs Ltd V LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 203259-001 Feb 3, 2014 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Hetero Labs Ltd Iii LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 079124-001 Sep 17, 2015 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Strides Pharma LAMIVUDINE AND ZIDOVUDINE lamivudine; zidovudine TABLET;ORAL 079128-001 May 13, 2015 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Viiv Hlthcare COMBIVIR lamivudine; zidovudine TABLET;ORAL 020857-001 Sep 26, 1997 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for lamivudine; zidovudine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare COMBIVIR lamivudine; zidovudine TABLET;ORAL 020857-001 Sep 26, 1997 ➤ Subscribe ➤ Subscribe
Viiv Hlthcare COMBIVIR lamivudine; zidovudine TABLET;ORAL 020857-001 Sep 26, 1997 ➤ Subscribe ➤ Subscribe
Viiv Hlthcare COMBIVIR lamivudine; zidovudine TABLET;ORAL 020857-001 Sep 26, 1997 ➤ Subscribe ➤ Subscribe
Viiv Hlthcare COMBIVIR lamivudine; zidovudine TABLET;ORAL 020857-001 Sep 26, 1997 ➤ Subscribe ➤ Subscribe
Viiv Hlthcare COMBIVIR lamivudine; zidovudine TABLET;ORAL 020857-001 Sep 26, 1997 ➤ Subscribe ➤ Subscribe
Viiv Hlthcare COMBIVIR lamivudine; zidovudine TABLET;ORAL 020857-001 Sep 26, 1997 ➤ Subscribe ➤ Subscribe
Viiv Hlthcare COMBIVIR lamivudine; zidovudine TABLET;ORAL 020857-001 Sep 26, 1997 ➤ Subscribe ➤ Subscribe
Viiv Hlthcare COMBIVIR lamivudine; zidovudine TABLET;ORAL 020857-001 Sep 26, 1997 ➤ Subscribe ➤ Subscribe
Viiv Hlthcare COMBIVIR lamivudine; zidovudine TABLET;ORAL 020857-001 Sep 26, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for lamivudine; zidovudine

Supplementary Protection Certificates for lamivudine; zidovudine

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0022 France ➤ Subscribe PRODUCT NAME: ABACAVIR SULFATE; LAMIVUDINE; REGISTRATION NO/DATE: EU/1/04/298/001 20041217
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Daiichi Sankyo
Mallinckrodt
Federal Trade Commission
Healthtrust
Fuji
Fish and Richardson
US Department of Justice
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot